Abstract Megalencephalic leukoencephalopathy with subcortical cysts is an autosomal recessive disease characterized by early onset macrocephaly; developmental delay; motor disability in the form of progressive spasticity and ataxia; seizures; cognitive decline; and characteristic magnetic resonance imaging findings. Mutations in two genes, MLC1 (22q13.33; 75 % of patients) or HEPACAM (11q24; 20 % of patients), are associated with the disease. We describe an adult MLC patient with moderate clinical symptoms. MLC1 cDNA analysis from lymphoblasts showed a strong transcript reduction and identified a 246-bp pseudoexon containing a premature stop codon between exons 10 and 11, due to a homozygous c.895-226 T>G deep-intronic mutation. This category of mutations is often overlooked, being outside of canonically sequenced genomic regions. The mutation c.895-226 T>G has a leaky effect on splicing leaving part of the full-length transcript. Its role on splicing was confirmed using a minigene assay and an antisense morpholinated oligonucleotide targeted to the aberrant splice site in vitro, which partially abrogated the mutation effect. 
Introduction
Megalencephalic leukoencephalopathy with subcortical cysts is an autosomal recessive disease whose essential features include macrocephaly (large head) with onset in infancy; motor delay followed by motor disability in the form of progressive spasticity and ataxia; seizures; and cognitive decline. Neuroimaging shows extensive symmetric white-matter changes with subcortical cysts [1] . Despite severe neurological abnormalities, MLC has a milder clinical evolution compared with other infantile forms of leukodystrophies, e.g., those with peroxysomal or lysosomal defects [2] .
Mutations in the MLC1 gene on chromosome 22q13.33 are found in ∼75 % patients (megalencephalic leukoencephalopathy cysts type 1 or van der Knaap disease, OMIM#604004) [3] . In about 20 % of patients, the disease is explained by mutations in the hepatocyte cell adhesion molecule precursor gene (HEPACAM) on chromosome 11q24.2. HEPACAM-associated MLC can be inherited in an autosomal recessive form (classified as MLC2A, OMIM#613925) or in a less severe autosomal dominant form of "transient" MLC with or without mental retardation and/or autism (MLC2B, OMIM#613926) [4] .
MLC1 is an oligomeric cytoplasmic membrane protein with eight predicted transmembrane segments. It is mainly localized in astrocyte-astrocyte junctions close to bloodand cerebrospinal fluid-brain barriers, Bergmann glia, and main axonal tracts [5] . Reported mutations interfere with MLC1 membrane localization [6] . A role in ion transport has been suggested due to its multi-pass membrane domains and the presence of an internal repeat similar to those found in ion channels [7] . Recently, it has been demonstrated that MLC1 plays a role in anion channel activity, and its mutations reduce the regulatory volume of astrocytes, a key process in osmotic perturbation buffering in the central nervous system [8] . It remains to be elucidated whether MLC1 acts as a volume-regulated anion channel (VRAC) or contributes to the activation/regulation of a VRAC [8] . HEPACAM is an MLC1 interactor, predominantly expressed in the central nervous system, thus explaining why alterations in these two different proteins give rise to the same phenotype [6, 9] .
Here, we describe a patient with MLC characterized by macrocephaly, juvenile-onset seizures, and subcortical cysts, with moderate symptoms and slow progression. We identified the causative mutation in a homozygous deep-intronic variant in MLC1 that introduces a pseudoexon with a premature stop codon and causes a leaky effect on splicing. The effect of the mutation on splicing was confirmed using a minigene assay and could be partially reverted in vitro with an antisense morpholinated oligonucleotide targeted to the aberrant splice site.
Materials and methods

Patients
The proband, clinically diagnosed with megalencephalic leukoencephalopathy with subcortical cysts, was from an Italian family (MLC-1-TO) with healthy relatives and 14 healthy siblings (Fig. 1a) . Peripheral blood was collected from 11 available family members (the mother and ten siblings) and a lymphoblastoid cell line (LCL) established from the MLC patient. Nine further cases were selected from a group of clinically and neuroradiologically defined MLC patients negative for mutations in known genes (E.B.). Informed consent was collected from all participants in the study.
DNA extraction and genetic analysis
Genomic DNA was extracted from peripheral blood (Qiagen, Hilden, Germany) following the manufacturer's instructions. Microsatellite markers at MLC1 (chromosome 22q13.33) and MLC2A (chromosome 11q24.2) loci were chosen within a 1.5 Mb distance from the genes and amplified using KAPAFast polymerase under the conditions specified by the manufacturer (KAPA Biosystems, Woburn, MA, United States). Oligonucleotide sequences were: 355c18, 5′-6FAM-gtgtcctgtgggtattccag and 5′-gaaccagggtgcagttcttg; D22S1169, 5′-6FAM-cacacacatgcacataatc and 5′-gaaccagggtgcagttcttg; chr11_124296, 5′-NED-cagctctaataagggcc and 5′-aagcct gcatgcctagagag; D11S4151, 5′-6FAM-gtcttcccaccttgg atatgggta, and 5′-aatgggcacctccaccctattagt. Amplification products were loaded into an ABI Prism 3100 Avant automated sequencer (Applied Biosystems, Foster City, CA, USA). Allele size was determined by comparison to a ROX-500 marker using the GeneScan software (Applied Biosystems). Haplotypes were manually reconstructed.
The 12 coding exons of the MLC1 gene (RefSeq NM_015166.3) were polymerase chain reaction (PCR)-amplified using primer and conditions reported in Online resources. Amplimers were purified using Exo-SAP (MBI-Fermentas, Vilnius, Lithuania) and directly sequenced using the Big-Dye terminator cycle sequencing kit ver. 1.1 with an ABI Prism 3100 Avant automatic sequencer (Applied Biosystems).
Expression analysis of MLC1
Total peripheral blood mononuclear cells (PBMC) were separated from blood using a Ficoll gradient. Total RNA was extracted using the RNeasy Plus Mini Kit (Qiagen) and retrotranscribed using the Transcriptor First Strand cDNA Synthesis kit (Roche Diagnostics, Mannheim, Germany). The expression levels of MLC1 were measured in a duplex real-time PCR assay using primers 5′-agcagagtgtcccagcaagt (exon 9), 5′-agacgtgaggctgcttatgg (exon 10), the 6FAM labeled UPL#22 probe (Roche Diagnostics), and a commercial VIC-labeled TATA-binding protein TaqMan assay as a reference (Hs00427620_m1, Applied Biosystems). Reactions were carried out on an ABI 7500 Fast real-time PCR machine using the ABI TaqMan universal PCR master mix according to the manufacturer's instructions (Applied Biosystems). Efficiencies of the two assays were in the 90-110 % range. Each experiment was performed in triplicate with tree unrelated healthy controls. The mean Ct value was used for calculations, using the comparative delta-delta Ct method described by [10] . cDNA mutation analysis and c.895-226 T>G mutation screening
The entire MLC1 coding region was divided into four partially overlapping fragments ranging from 254 to 416 bp (Fig. 2a, regions A to D) , gel-analyzed, and sequenced. The effect on cDNA splicing of the c.895-226 T>G mutation was checked using the Web applications Splice Site Prediction (http://www.fruitfly.org/seq_tools/splice. html) [11] .
The mutation c.895-226 T>G was confirmed in genomic DNA (gDNA) by direct sequencing after PCR-amplification with KAPA fast polymerase using the primers 10bF 5′-gtgctccgtggtcactctct and 10bR 5′-cgagtcggagccccagtaac at the annealing temperature of 60°C, under the conditions specified by the manufacturer (KAPA Biosystems).
A specific reverse-transcription-polymerase chain reaction (RT-PCR) from ψ10b to exon 12 was performed using primers 11Fb: 5′-cagtggctcggtcactttta and c12R: 5′-gctctccaggctttctcctt and the following conditions-1 min at 95°C, followed by 14 cycles of 10 s at 95°C, 10 s at annealing temperature (56°C)+7°C-0.5°C/cycle and 10 s at 72°C; then 25 cycles consisting of 10 s at 95°C, 10 s at annealing temperature 56°C and 10 s at 72°C with KAPA fast polymerase (KAPA Biosystems).
The mutation c.895-226 T>G in IVS10 introduces a MspI restriction endonuclease site and was tested in controls using the MspI restriction endonuclease (MBIFermentas, Vilnius, Lithuania): The gDNA amplimers of 200 healthy controls, obtained with primers 10bF+10bR and under conditions reported above were digested with MspI endonuclease. In the presence of the c.895-226 G mutation the 469 bp amplimer split into two bands (348+ 121 bp).
Minigene assay A minigene assay was established to test the effects of the MLC1 c.895-226 T>G (IVS10) and the c.1059+16 G>A (IVS11, rs#5771338) variants on splicing. Details are reported in Online resources.
Band quantification was performed with the ImageLAB software (Bio-Rad, Hercules, CA, USA) and statistical analyses with GraphPad Prism software (Graphpad Software, La Jolla, CA, USA).
Tissue expression analysis
We performed a semiquantitative real-time RT-PCR analysis amplifying fragment D (see Fig. 2a ) in cDNAs of adult human tissue (Human MTC Panel I, #636742 Clontech Laboratories, Mountain View, CA, USA) and fetal human tissue (Human Fetal MTC Panel, #636747 Clontech Laboratories) as templates using the primers and conditions specified in Online resources.
Correction of MLC1 aberrant splicing by antisense morpholino oligonucleotide
The 25-mer antisense morpholinated oligonucleotide (AMO) (ATCAGCTTGTGTTCAACATACCGGA, the mutation site is underlined) was designed to target the aberrant 3′ splice site activated by the c.895-226 T>G mutation in pre-mRNA. The AMO was synthesized and purified by Gene-Tools (LLC, Philomath, OR). Endo-Porter (GeneTools) was used to help lymphoblastoid cells incorporate the AMO. For AMO treatment, 5×10 5 LCLs cells were resuspended in 0.5 ml 5 % FBS/RPMI 1640 medium, and AMO was added directly to the medium at the concentration indicated in Fig. 3d , together with Endo-Porter (4 μl). Equal volumes of Endo-Porter were added to untreated cell cultures as controls. After 48 h incubation, cells were collected and rinsed in PBS. Total RNA was extracted and cDNA retrotranscribed as described above. For RT-PCR, primers c10F and c12R were used to amplify both the full-length and the mutant transcripts (see Online resources).
Results
Clinics and neuroradiology
The patient, a woman aged 49 years, is the eighth of 15 siblings from healthy and reportedly unrelated parents.
After an uneventful delivery, macrocephaly was noted during her first year of life, leading to an unspecific diagnosis of hydrocephalus (no radiological exams related to this diagnosis are available). A mild delay in psychomotor development was noticed, and a very mild learning impairment was reported during schooling.
At 6 years of age, several episodes of anxiety, sudden fear, and claustrophobia occurred that were interpreted as epileptic seizures and treated with phenobarbital. At 22 years, the patient presented her first tonic clonic seizures. The EEG documented bursts of sharp waves, and a CT scan showed a diffuse supratentorial white matter hypodensity. At neurological examination, very mild cerebellar and pyramidal signs were noted.
At 27 years, the patient acutely developed psychiatric symptoms (delusions and visual hallucinations) that required hospitalization and treatment with neuroleptic drugs. She gradually improved, and 5 years later, the neuroleptic and the antiepileptic treatments were discontinued without recurrence of both psychiatric symptoms and epileptic seizures.
The patient was stable until 44 years when she was hospitalized after an apparently accidental fall from a bicycle, with minor head trauma accompanied by loss of consciousness. At hospital admission, marked psychomotor agitation and motor impairment of right arm and leg were present, followed by prolonged coma. The patient remained unresponsive to verbal and nociceptive stimuli for few days. Once full consciousness was regained, she displayed a right hemiparesis with marked spasticity of the upper arm. Soon after the hospitalization, a CT scan was performed that excluded posttraumatic lesions and confirmed diffuse hypodensity of the supratentorial white matter. At MRI, a diffuse, symmetric signal abnormality involving frontal and parietal white matter and several subcortical cysts of the temporal lobes were present. The radiological picture prompted a diagnosis of MLC (Fig. 1c-d) .
Notably, soon after hospitalization, an increase in troponin levels together with evidence of septal and anterior hypokinesia at the transthoracic echocardiography suggested acute myocardial infarction. Cardiac enzymes and echocardiography normalized after 2 days, supporting a diagnosis of Tako-Tsubo syndrome [12] .
Since then, the patient has undergone regular neurological follow-up that documented a progressive worsening of her motor skills, and 4 years after the acute event, the patient was wheelchair-bound. At the latest neurological examination, the patient presented truncal and gait ataxia, weakness and motor impairment of the right arm and of both legs, marked spasticity of right arm and leg, hypereflexia, bilateral Babinsky sign, intentional tremor of hands, dysarthric speech, and mild apraxia.
Genetic analyses
We exploited the availability of the genomic DNA from the mother and nine siblings of the patient for a linkage analysis to identify which of the two known MLC loci could be associated with the disease. Using microsatellite markers flanking the genes, MLC2A locus was excluded because the patient and one of her healthy brothers carried the same haplotypes at this locus (Fig. 1a, II-2 and II-8) . On the other hand, the patient was homozygous for two markers close to the MLC1 locus that are inherited from both parents, Fig. 3 Minigene assay and AMO strategy. The effect of c.895-226 T>G mutation on splicing was studied by a minigene assay (a). Part of MLC1 intron 10 was subcloned into a pSPL3 eukaryotic modified expression vector and transfected into HeLa cells. RT-PCR, using primers mapping into vector synthetic exons b1 and b2, displayed a 263 bp band corresponding to the spliced product between synthetic exons b1 and b2; an additional 509 bp band is present in the mutated clone only (pMLC1-c.895-226 G) and corresponds to an insertion of a 246 bp pseudoexon (b). The pseudoexon inclusion in the transcript occurs at a low efficiency, as seen by faint band intensity. Asterisk indicates an unexpected band (∼400 bp), probably due to an internal splice site present in both the wild-type and mutated constructs. c-d Antisense morpholino oligonucleotide (AMO) strategy. Increasing amounts of AMO were transfected in patient's LCLs (II-8). The pseudoexon inclusion into MLC1 transcript was almost completely abrogated after AMO treatment. CTRL indicates a wild-type control. MW1, 100 bp ladder plus (MBI-Fermentas); MW3: DNA 1 kb ladder (MBI-Fermentas) suggesting a possible consanguinity (Fig. 1a) . No sibling shared the same homozygous haplotype.
Considering MLC1 as the possible disease-associated gene, we tested its involvement in the disease by measuring its expression in PBMCs. Real-time RT-PCR showed that MLC1 mRNA was strongly reduced in our patient (≈17 %± 4 % compared with controls, p<0.0001 Fig. 1b) . We sequenced the 12 MLC1 coding exons, flanking intron boundaries, and part of the 5′-and 3′-UTR without finding any mutation. The minor alleles of two known SNPs in intron 4 (rs#79301) and intron 11 (rs#5771338) were found in homozygosis, further suggesting autozygosity/consanguinity.
MLC1 cDNA was amplified in four overlapping fragments (Fig. 2a) . Fragment D showed the 363 bp normal band and two unexpected bands: The shorter was present in both the patient and controls and was found to be an alternative splicing isoform (see below) (Fig. 2b, 198 bp) ; the larger was present in the patient only (Fig. 2b, 609 bp) . Sequencing showed that the 609 bp band corresponded to the insertion of one pseudoexon of 246 bp in intron 10 (named exon ψ10b), which contains in frame stop codons, probably causing a nonsense-mediated decay of the mRNA and thus explaining its reduced levels.
The cDNA and the genomic sequence surrounding the pseudoexon revealed a single possible causative mutation: a T>G homozygous change, c.895-226 T>G (Fig. 2c) . This change is not reported as a polymorphism in the dbSNP v.135. Calculating the splice site scores (i.e., strength of splicing) of the sequences adjacent to the 246 bp inclusion, the c.895-226 T>G variant changes the splice site score from 0.20 in the wild-type to 0.95 in the mutant, creating a novel donor splice site and thereby resulting in the activation of a cryptic AG acceptor splice site 246 bp upstream (Fig. 2c) . Using a specific primer within the pseudoexon (11Fb) and a reverse primer on exon 12 (c12R), we demonstrated the presence of a 240 bp band in the patient's cDNA only and not in ten normal controls (Fig. 2d) . Finally, the c.895-226 T>G change was not found in a group of 200 normal healthy controls from the same geographical region using restriction PCR digestion (see Fig. 2e ), further evidence that it was not a rare polymorphism. We also screened a group of nine clinically identified MLC patients, negative for mutations in both MLC1 and HEPACAM genes, and did not find the c.895-226 T>G, suggesting that it is a private mutation.
Minigene assay
Minigene constructs were obtained by cloning 469 bp of genomic DNA from IVS10, containing the pseudo exon ψ10b and flanking sequences, from patient II-8, and a healthy sibling (II-4) into the plasmid vector pSPL3 (Invitrogen) (Fig. 3a) . Figure 3 shows the characteristic posttransfection-spliced products of the two minigene constructs, as determined by direct PCR product sequencing. Both mutated and wild-type clones showed a strong band corresponding to the empty vector (Fig. 3b, 263 bp) . However, the construct pMLC1-c.895-226 G containing the mutation showed an additional larger segment containing the pseudoexon ψ10b (Fig. 3b, 509 bp) . Both constructs also showed an unexpected band of approximately 400 bp, interpreted as nonspecific (Fig. 3b, asterisk) .
Correction of MLC1 aberrant splicing by antisense morpholino oligonucleotide (AMO)
We designed a specific AMO to mask the cryptic 5′ splice site activated by the c.895-226 T>G mutation and delivered them to the patient's lymphoblastoid cell line. Correction of splicing could already be observed at the lower dosage of 10 μM AMO, as demonstrated by RT-PCR, with the almost complete abrogation of the 246 bp pseudoexon (Fig. 3d) . Increasing the AMO dose did not notably change the band pattern. We also noted a remarkable reduction of the MLC1b isoform (see below) in AMO-treated cell lines.
MLC1 has an alternative isoform with exon 11 skipping
We further observed, in the mRNA extracted from lymphoblasts of both the patient and healthy controls, the presence of an MLC1 isoform lacking exon 11, subsequently named MLC1b. Because this variant is not reported in the genomic databases (see UCSC genome browser), we decided to investigate its expression pattern and its origin. We analyzed MLC1/MLC1b expression in several human tissue by RT-PCR using forward primer in exon 10 (c10F) and a reverse primer in exon 12 (c12R) and showed that the MLC1b isoform is ubiquitously expressed at low levels, with the exception of fetal brain, where the band corresponding to MLC1 and MLC1b isoforms have comparable intensity (Fig. 4a) .
Performing the same test on lymphoblasts from healthy controls, we noted the MLC1b isoform intensity was variable and undetectable in some. Hypothesizing the presence of a genomic variant affecting splicing, we sequenced exon 11 and flanking introns and noted that controls containing MLC1b were also carrying the minor allele "A" of rs#5771338, located at IVS11+16 position. This variant is a polymorphism with an allelic frequency of 12 % in people of Northern and Western European ancestry (CEU population, http://www.1000genomes.org).
Discussion
According to "The Human Gene Mutation Database" (http://www.hgmd.org/), ∼10 % of reported mutations in disease-associated genes are splicing mutations. Although most of them affect consensus sites, deep intronic mutations are increasingly being detected in human diseases: Recent examples include HPRT deficiency, Usher syndrome type 2, cystic fibrosis, and hemophilia A [13] [14] [15] [16] . The importance of evaluating such splicing defects is well known and has been underlined for MLC too [17] .
Deep intronic mutations are easily overlooked, because they are not targeted by standard genetic screening and are missed even by more recent whole-exome sequencing methods. They are, however, particularly interesting from a therapeutic point of view. In case of a deep intronic mutation, the wild-type splice sites remain unchanged and thus may be utilized to force the cell to skip the pseudoexon. Such achievement could be obtained using antisense oligonucleotides that, targeting the donor, acceptor, or branch site of the pre-mRNA, result in the skipping of the relative pseudoexon. The rescue of splicing defects has been demonstrated both in vitro and in vivo, and clinical trials are already in phase II for patients with Duchenne muscular dystrophy [18, 19] .
The diagnosis in this patient was initially puzzling. Clinical features overlapped with the MLC phenotype associated with MLC1 mutations; however, macrocephaly, the first sign generally leading to diagnosis in the first years of life, was overlooked, together with a minor impairment and late onset (22 years) epileptic seizures which responded well to therapy. Only at 44 years, an MRI exam, performed following head trauma, led to the diagnosis of MLC. Genetic confirmation was performed because the presence of only a single affected subject among 15 siblings was barely suggestive of an autosomal recessive disease.
Linkage analysis with microsatellite markers and expression analyses by real-time RT-PCR on PBMCs proved that the disease was linked to the MLC1 locus. The absence of point mutations in the MLC1 gene coding region prompted us to screen its cDNA. We found a deep intronic mutation in homozygosis (intron 10, c.895-226 T>G), indicative of unreported consanguinity in the family. The c.895-226 T>G change activates a donor splice site (Tgt>Ggt) that results in the inclusion of a 246 bp pseudoexon between exon 10 and 11. This mutation, not present in the dbSNP database, was also absent among 400 normal chromosomes, excluding that it might be a rare polymorphism. Further proof of its pathogenicity came from a minigene assay, which demonstrated inclusion of the pseudoexon only in the transcript from plasmids carrying the mutation. The minigene construct yielded only a partial inclusion of the pseudoexon, suggesting a "leaky" mechanism of the mutation.
Our patient had a dramatic and irreversible deterioration after trauma, presenting an acute hemiparesis that required ruling out a post-traumatic lesion or an ictal event that, in turn, caused the fall from the bicycle. An acute deterioration caused by head trauma, although with gradual improvement, has been reported in MLC patients [20] , and this also reminds of stress-related worsening seen in other leukoencephalopathies such as vanishing white matter disease and leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation [21] [22] [23] . The patient also presented a TakoTsubo syndrome, a transient left ventricular systolic dysfunction in the absence of obstructive coronary disease. TakoTsubo syndrome has been related to acute conditions leading to sympathetic dysregulation such as status epilepticus or subarachnoid hemorrhage. Few cases have been described in association to reversible posterior leukoencephalopathy, an acquired and transient white matter disorder, whose pathogenesis is still unclear [12] .
Using an antisense morpholinated oligonucleotide (a stabilized antisense oligonucleotide variant) targeted to the cryptic donor splice site of the pseudoexon, we were able to restore in vitro normal splicing, even at the lowest doses, further proving that the c.895-226 T>G variant was causing the pseudoexon activation .
Even if MLC1 is a brain-specific protein, our work shows that its transcript is easily detectable by RT-PCR in white blood cells, suggesting that patients testing negative for MLC1 mutations (and probably also HEPACAM) should be screened for cDNA anomalies. Fig. 2c ) and 12 (c12R in Fig. 2c ), two amplification products of 317 and 152 bp were detected in human tissues. Sequencing revealed the former corresponding to exons 10-11-12, and the latter to exons 10-12. The second transcript variant, named MLC1b, is not reported in the genomic databases (e.g., genome.ucsc.org). The relative expression of the two transcripts is variable in different tissues; MLC1b is highly expressed in fetal brain. b RT-PCR analysis from three control LCLs showed that MLC1b is present only in carriers of the c.1059+16A variant at SNP rs#5771338 A variant transcript of MLC1 without exon 11 (MLC1b), unreported in the databases, may also be related to the phenotype. We showed that MLC1b is present in a small percentage of transcripts in normal individuals (<5 %) carrying the G>A SNP 16 bp downstream exon 11 (rs#5771338). In our patient, homozygous for the A variant, the splicing machinery, in the presence of c.895-226 T>G mutation, may attempt a rescue of a functional MLC1 product, leading to an increase of the MLC1b isoform. This conclusion is also supported by the decrease MLC1b after AMO treatment. The role of the MLC1b isoform should be investigated in fetal brain, where it is highly expressed. We might speculate that MLC1b has a different function compared with MLC1, given its low expression in adult brain and the description of disease-associated splicing mutations possibly resulting in the skipping of exon 11, encoding for the transmembrane domain [24] .
Three main conclusions are relevant from our work: (1) The identification of deep intronic mutations can solve clinical cases assigning the mutated gene to the disease; (2) such mutations may shed light on new regulatory splicing elements; and (3) they may be used to study a therapeutic strategy based on antisense oligonucleotides. This having been said, each new AMO for each patient would also require preclinical trials for safety and efficacy, a major financial deterrent to personalized medicine that may need further consideration by regulatory agencies.
